SciClone Expects FY14 Sales Revenue Of $130 Mln- $135 Mln

(RTTNews) - SciClone Pharmaceuticals, Inc. (SCLN), a specialty pharmaceutical company, Thursday said it anticipates 2014 sales revenue of $130 million to $135 million, representing an approximate 30 percent increase of its core business revenue.

The company noted that its core business revenue excludes all Sanofi products and certain Pfizer products, including Adriamycin and Daunoblastina.

Friedhelm Blobel, SciClone's Chief Executive Officer, said, "The China pharmaceuticals market continues to expand at a rate that surpasses Western markets. … We are confident that ZADAXIN has significant growth potential, both in the current indications for which it is used, as well as in potential new indications, such as sepsis and non-small cell lung cancer. We are also excited about the expansion of our cardiovascular franchise with potential new market entrants, Neucardin and ProFlow, which represent large market opportunities and long-term growth strategies for our Company."

In addition, the company said it expects 2013 year-end cash and investments to be approximately $86 million. Excluding the impact of the in-licensing of new products, the ongoing stock repurchase program and the overdue accounts receivable payment from Sanofi, which is currently being negotiated, the company's cash and investments would have been approximately $107 million.

SciClone expects to report its complete fourth quarter and full-year 2013 financial results in March 2014.